Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

NCT03175172 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Study was stopped due to low enrollment and lack of clinical activity.

Conditions

Malignant Pleural Mesothelioma

Interventions

BIOLOGICAL: CRS-207
BIOLOGICAL: Pembrolizumab

Sponsor

Aduro Biotech, Inc.

Collaborators

[object Object]